Loading...
Thumbnail Image
Item

HOST FACTOR-DIRECTED INHIBITION OF LATE SARS-COV-2 LIFE CYCLE STAGES

Date
2023
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
dissertation
Research Area
Jurisdiction
Other Titles
See at
Abstract

The sudden emergence of Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), the etiologic agent of Coronavirus Disease 2019 (COVID-19), burgeoned into a multi-year pandemic that continues to test the world’s healthcare systems and economies. Early therapeutic development led to multiple compounds that target early stages of the SARS-CoV-2 lifecycle with varying degrees of efficacy: monoclonal antibodies (e.g., Casirivimab, Tixagevimab) to block virus entry; protease inhibitors (e.g., Paxlovid) to block proteolytic cleavage of nonstructural proteins translated shortly after viral entry; and nucleoside analogues (e.g., Molnupiravir) to block viral RNA replication. However, later stages of the SARS-CoV-2 life cycle are relatively understudied and, consequently, late-stage inhibitors that could prove more effective or work synergistically with early-stage inhibitors are lacking. This dissertation work describes two host proteins that inhibit later SARS-CoV-2 lifecycle stages when modulated. PIKfyve inhibition was shown to block late lifecycle stages of SARS-CoV-2, in addition to broadly inhibiting early and middle stages, but exacerbated disease in a COVID-19 mouse model. Overexpression of the interferon stimulated gene 2’,3’-cyclic-nucleotide-phosphodiesterase (CNP) in vitro was shown to inhibit virion assembly by blocking SARS-CoV-2-induced mitochondrial depolarization and reactive oxygen species release. Additionally, overexpression of CNP in Balb/c laboratory mouse lungs reduced SARS-CoV-2 titers to undetectable levels at 2- and 4-dpi. Importantly, this work has identified host factors that could be further developed into therapeutic targets.

Data Availibility
Data / Code Location
Table of Contents
Description
Molecular Microbiology and Immunology
University of Maryland at Baltimore
Ph.D.
University of Maryland, Baltimore, School of Medicine, Ph.D., 2023
Citations
Altmetric:
Series/Report No.
Sponsors
Rights/Terms
Identifier to cite or link to this item
Scopus Identifier
Embedded videos